In a nutshell The study aimed to investigate the rate of response (seroconversion) to SARS-Cov-2 vaccination in patients with blood cancers. This study concluded that seroconversion rates in these patients were significantly lower than that of healthy controls. Some background The severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2)...
Read More
In a nutshell This study evaluated the effectiveness of salvage autologous hematopoietic cell transplantation (ASCT) performed with stem cells obtained after previous transplantation in patients with relapsed multiple myeloma (MM). The data showed that salvage ASCT performed with stem cells remobilized after previous transplantation is a good treatment...
Read More
In a nutshell This study evaluated the long-term effectiveness and safety of isatuximab (Sarclisa) in combination with pomalidomide (Pomalyst) and low-dose dexamethasone (Decadron) (Pd) in previously treated patients with relapsed or refractory (r/r) multiple myeloma (MM). The data showed that isatuximab plus Pd combination significantly improved the...
Read More
In a nutshell This study evaluated the effectiveness and safety of etoposide (Etopophos) combined with cytarabine (Cytosar-U) plus granulocyte colony-stimulating factor (G-CSF, Neupogen) in patients with multiple myeloma (MM) for stem cell mobilization. The data showed that etoposide combined with cytarabine plus G-CSF was safe and effective for the...
Read More
In a nutshell The study aimed to investigate if immunocompromised patients with blood cancers benefit from COVID-19 vaccination. This study concluded that these patients should not be excluded from COVID-19 vaccination. Some background Patients with blood cancers are at high risk for severe forms of COVID-19 disease due to lower immune...
Read More
In a nutshell This study evaluated the effectiveness and safety of an all-oral combination of ixazomib (Ninlaro), lenalidomide (Revlimid), and dexamethasone (Decadron) in transplant-eligible patients with newly diagnosed multiple myeloma (MM). The data showed that this combination was effective with manageable side effects in these...
Read More
In a nutshell This study evaluated the effectiveness and safety of ixazomib (Ninlaro)-dexamethasone (Decadron) (ixa-dex) versus pomalidomide (Pomalyst)-dexamethasone (pom-dex) combination for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). The data showed that ixa-dex was safe and as effective as pom-dex...
Read More
In a nutshell This study evaluated the effectiveness and safety of adding ixazomib (Ninlaro) to lenalidomide (Revlimid) maintenance therapy after autologous stem cell transplant (ASCT) in patients with newly diagnosed multiple myeloma (MM). The data showed that the addition of ixazomib to lenalidomide maintenance improved survival without cancer...
Read More
In a nutshell This study compared the effectiveness and safety of using daratumumab (Darzalex) with lenalidomide (Revlimid) and dexamethasone (Decadron)(D-Rd) to lenalidomide and dexamethasone (Rd) treatment in patients with newly diagnosed multiple myeloma (NDMM), based on frailty levels. The data showed that D-Rd was more effective than Rd at improving...
Read More
In a nutshell This study aimed to investigate the effect of idecabtagene vicleucel (ABECMA; ide-cel) treatment on health-related quality of life (HR-QoL) in patients with relapsed or refractory (r/r) multiple myeloma (MM). This study concluded that this treatment improves HR-QoL for these patients. Some...
Read More
Two of our most popular previous blog posts described free vacation opportunities for adults with cancer. Given the uncertainty of the past two years, we thought it was time for an update. Here is a short list of organizations that have made it their mission to provide needed respite to those affected by cancer. Each has been verified to have...
Read More
In a nutshell This study evaluated the safety and effectiveness of selinexor (Xpovio) in combination with carfilzomib (Kyprolis) and dexamethasone (Decadron) (XKd) in patients with relapsed/refractory (r/r) multiple myeloma (MM) that still responded to carfilzomib. The data showed that weekly administered XKd was highly effective and...
Read More
